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Although cartilage degeneration characterizes human osteo-
arthritis (OA), changes also involve the participation of the
synovial membrane and the subchondral bone.
In this review, attention will be focused on current knowl-
edge of the major factors participating in the degeneration
of OA articular joints tissues. Firstly, we will address the
biochemical agents involved in the destruction of cartilage
and synovial membrane. This will be followed by a brief
survey of the most important modulatory factors of
proinflammatory cytokines as well as biological agents as
potential therapeutics. Emphasis will then be placed on the
possibility of an interaction between subchondral bone and
cartilage as an integral part of the disease, leading and/or
contributing to cartilage destruction in OA; do changes in
one cause alterations in the other.This paper was first published as a review in Osteoarthritis Cart
1998;6:374–6.Pathophysiology of osteoarthritis
Osteoarthritis (OA) is an idiopathic disease character-
ized by a degeneration of articular cartilage. A breakdown
of the cartilage matrix leads to the development of fibril-
lation and fissures, the appearance of gross ulcerations,
and the disappearance of the full thickness surface of the
joint. This is accompanied by bone changes with osteo-
phyte formation and thickening of the subchondral plate.
Moreover, at the clinical stage of the disease, changes
caused by OA involve not only the cartilage but also the
synovial membrane, where an inflammatory reaction is
often observed.1
A great deal of attention is focused on identifying the
protease responsible for the initial occurrence of matrix
digestion. Current knowledge indicates an important
involvement of matrix metalloproteases (MMP). Of this
family, members from three groups in human articular
tissues have been identified as being elevated in OA, the
collagenases, the stromelysins and the gelatinases.
Another group of MMP, localized at the cell membrane
surface, has recently been discovered, and named mem-
brane type MMP (MT-MMP). Four members have been
identified. Although MT1-MMP possesses properties of
collagenase, and both MT1-MMP and MT2-MMP are able
to activate gelatinase 72 kD and collagenase-3, the
relevance of these enzymes to OA has yet to be
determined.371MMP biologic activity is controlled physiologically by
specific tissue inhibitors of metallo-proteases (TIMP) or by
their activation. Enzymes from the serine- and cysteine-
dependent protease families, such as the plasminogen
activation/plasmin system and cathepsin B respectively,
have been proposed as activators, and enhanced levels of
urokinase (uPA) and plasmin have been identified in
human OA cartilage.2 Other enzymes have also been
found to act as MMP activators. For example, stromelysin-1
activates collagenase-1, collagenase-3 and gelatinase
92 kD; collagenase-3 activates gelatinase 92 kD, MT-MMP
activates collagenase-3, and gelatinase 72 kD potentiates
the latter activation; MT-MMP also activates gelatinase
72 kD.
Current evidence suggests that proinflammatory
cytokines are responsible for the catabolic process occur-
ring in the pathological tissues. They appear to be first
produced by the synovial membrane, and diffused into the
cartilage through the synovial fluid, where they activate the
chondrocytes to produce proinflammatory cytokines. In OA
synovial membrane, it is the synovial lining cells that play a
major role as inflammatory effectors of which interleukin
(IL)-1â, Tumor necrosis factor (TNF)-Æ, IL-6, leukemic
inhibitor factor (LIF) and IL-17 appear most relevant to the
disease.
Osteoarthritis data strongly support the concept that
IL-1â, and perhaps TNF-Æ, are the major catabolic systems
involved in the destruction of joint tissues, and may consti-
tute the in-situ source of articular tissue degradation. It is
still unclear whether IL-1â and TNF-Æ act independently or
in concert to induce the pathogenesis of OA, or if a
functional hierarchy exists between these proinflammatory
cytokines. In animal models, it has been shown that block-
ing IL-1 or its activity is very effective in preventing cartilage
destruction,3 whereas blocking TNF-Æ results in decreased
inflammation.4 Both these cytokines have been found in
enhanced amounts in OA synovial membrane, synovial
fluid and cartilage.
IL-6 has also been proposed as a contributor to the OA
pathological process by: (1) increasing the amount of
inflammatory cells in synovial tissue; (2) stimulating the
proliferation of chondrocytes; and (3) by inducing an ampli-
fication of the IL-1 effects on the increased MMP synthesis
and inhibition of proteoglycan production. However, as IL-6
can induce the production of tissue inhibitor of metallopro-
teases (TIMP), and not MMP themselves, it is believed that
this cytokine is involved in the feedback mechanism that
limits enzyme damage.
LIF is another cytokine of the IL-6 family that is upregu-
lated in OA synovial membrane and fluid, and produced
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cytokines, IL-1â and TNF-Æ.5 This cytokine stimulates car-
tilage proteoglycan resorption, as well as MMP synthesis
and nitric oxide (NO) cellular production.6 However, its role
in OA has not yet been clearly defined.
IL-17 is a newly discovered cytokine of 20–30 kD
present as a homodimer and with variable glycosylated
polypeptides. The nature of the tissue distribution of IL-17
receptor (R) appears ubiquitous. IL-17 upregulates a
number of gene products involved in cell activation includ-
ing the proinflammatory cytokines, IL-1â, TNF-Æ and IL-6,
as well as MMP, in target cells such as human macro-
phages.7 IL-17 also increases the production of
NO in chondrocytes.8 The role of LIF, in OA remains
undetermined.
In addition, the inorganic free radical NO has been
suggested as a factor that promotes cartilage catabolism in
OA. Compared to normal, OA cartilage produces a larger
amount of NO, both under spontaneous and proinflam-
matory cytokine-stimulated conditions9 resulting in an
enhanced expression and protein synthesis of the inducible
NO synthase (iNOS). A high level of nitrite/nitrate has been
found in the synovial fluid and serum of arthritic patients.
In the inflammatory response of OA articular cells, the
changes in cyclooxygenase-2 (COX-2) expression and/or
activity seem one of the major determinants for prostaglan-
din (PG)E2 production. While the induction of COX-2 and
iNOS appear to be separate processes, interaction in some
target cells between these two systems was recently
reported;10 the NO stimulation of IL-1â and TNF-Æ-induced
COX-2 expression was suggested to be mediated by cyclic
quanosine monophosphate (cGMP). However, in an in-vitro
study on chondrocytes, it was shown that inhibition of NO
production enhanced PGE2 production.11
Natural inhibitors capable of directly counteracting the
binding of the cytokine to cells or reducing the proinflam-
matory level have been identified, and can be divided into
three categories based on their mode of action. The first
inhibitor category is a receptor-binding antagonist of which
to date only the IL-1 receptor antagonist has been found.
The second category is the soluble receptors for IL-1â and
TNF-Æ that are truncated forms of the receptors. Other
natural inhibitors able to reduce proinflammatory cytokine
production and/or activity are the cytokines having anti-
inflammatory properties. Four such cytokines, namely
transforming growth factor (TGF)-â, IL-4, IL-10 and IL-13,
have been identified as able to modulate various inflam-
matory processes including a decreased production of
proinflammatory cytokines such as IL-1â and TNF-Æ, as
well as some proteases, and an upregulation of IL-1Ra and
TIMP production.
Current therapeutic strategies of antagonizing IL-1â and
TNF-Æ with either receptor blockade (with IL-1Ra) or
molecular quenching (with IL-1R or TNF-R soluble recep-
tors) have proven valuable in other arthritic diseases and in
animal models of OA. Moreover, in-vitro therapeutic effects
of a selective inhibitor of iNOS on the progression of lesions
in experimental arthritis and OA12 models have recently
been reported.
In addition to degeneration of the articular cartilage, OA
involves changes in the surrounding bone. The recently
expanded body of knowledge concerning the subchondral
bone provides the basis upon which we may assert that this
tissue is intimately involved in the pathology of OA. It is
suggested that thickening of the subchondral bone may
participate in the progression of OA. Whether bonesclerosis initiates or is involved in the progression of
cartilage loss remains a matter of debate.
Opposing concepts can explain a stiffening of the
subchondral bone. In subchondral bone, the healing of
trabecular microfractures, which are present due to repeti-
tive impulse loading of the joint and remodeling of the bony
internal architecture to better resist these stresses, can
generate a stiffer bone that is no longer an effective shock
absorber.13,14 Conversely, subchondral bone stiffness may
be part of a more generalized bone alteration leading to
increased bone mineral density/volume.
The hypothesis that abnormal OA osteoblasts directly
influence cartilage metabolism has recently been put for-
ward.15,16 In one study15 it was shown that conditioned
media from primary osteoblasts of OA patients versus
subjects without arthritis significantly altered glyco-
saminoglycan release from normal cartilage in vivo, while
cytokine release from these cells remained intact. Recently,
Hilal et al.16 reported that in vitro primary cultures of
osteoblasts from human OA subchondral bone have an
altered phenotype, and that the plasminogen activator
(urokinae)/plasmin system activity and IGF-1 levels are
elevated in these cells, explaining the above observations.
Although cartilage degeneration characterizes human
OA, alterations of this disease also involve the participation
of the synovial membrane and subchondral bone. Both
clinical and laboratory evidence indicate an altered
subchondral bone metabolism in OA, possibly due to
abnormal osteoblast behavior. Coupled with mechanical/
chemical stresses, abnormal OA osteoblasts would then
accelerate subchondral bone formation, which would
enhance the mechanical pressure on the overlying carti-
lage in supporting joints, promoting further deterioration
and cartilage erosion. The role for a local factor(s) pro-
duced by osteoblasts (including PA/plasmin and IGF sys-
tems) promoting cartilage breakdown and/or increasing
subchondral bone turnover is gaining support.
The current understanding of the factors involved in this
disease has evolved greatly during recent years. A better
comprehension of the modulating factors as well as the
major regulators has and will continue to generate new
insights into a more accurate identification of effective
targets having therapeutic potential in the treatment of OA.
The future holds great promise for the development of new
and successful approaches to the treatment of this disease.References
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